Experts provide detailed review of antiplatelet therapy considerations in women

In the current issue of Cardiovascular Innovations and Applications (Special Issue on Women's Cardiovascular Health, Volume 3, Number 4, 2019, Guest Editor Gladys P. Velarde) pp. 363-373(11); DOI: https://doi.org/10.15212/CVIA.2017.0079 Khadeeja Esmail and Dominick J. Angiolillo from the University of Florida Medical School, Gainesville, FL, USA review antiplatelet therapy considerations in women.

The authors provide a detailed review of the available evidence on antiplatelet therapy for IHD, chronic-stable and unstable, and how female sex platelet biology has important implications on outcomes. Some important sex considerations in therapy emerge from this article which emphasizes that despite biological differences and a high bleeding risk, women do receive benefit from current and novel antiplatelet agents and how these are still underutilized in women. A summary of the impact of gender on outcomes in pivotal recent trials is provided. Coronary artery disease (CAD) is the leading cause of death worldwide, but because of several factors, one of which is antiplatelet therapy, the mortality rates have steadily declined. However, women continue to experience higher CAD mortality rates than men. This may be explained by differences in comorbidities, increased time to presentation, higher bleeding rates, and differences in management. There are numerous landmark trials in the field of antiplatelet therapy; however, women are consistently underrepresented in these trials. The results of these trials reveal that women experience the same benefit as men from antiplatelet therapy but experience higher bleeding rates; therefore bleeding-reduction strategies are imperative in this patient population. This article provides an overview of the available evidence on CAD in women and its implications for antiplatelet medications.

This article forms part of a special issue on Women's Cardiovascular Health, guest edited by Gladys P. Velarde. Recent decades have witnessed great progress in the treatment of cardiovascular disease (CVD). Due to improved therapies, preventive strategies and increased public awareness, CVD (stroke, heart failure, ischemic heart disease, peripheral arterial disease and congenital heart disease) mortality has been on the decline over this span of time for both genders. Unfortunately, the decline has been less prominent for women, especially women of color. Once viewed as a man's disease, CVD remains the leading cause of mortality for women in the United States and is responsible for a third of all deaths of women worldwide and half of all deaths of women over 50 years of age in developing countries. In the United States, CVD far outpaces all other causes of death, including all forms of cancer combined. The statistics are sobering with about one female death in the United States every 80 seconds from CVD. That represents close to 400,000 deaths per year according to the more recent statistics. Of these, more than one quarter of a million women will die this year from ischemic heart disease (IHD) which includes obstructive and non-obstructive coronary disease, and about 64% of women who die suddenly of IHD have no prior symptoms. Despite a significant number of females with known CVD and increased awareness among women of heart disease as their major health threat, a substantial proportion of women (46% as per the most recent American Heart Association survey) remain unaware of their cardiovascular risk and continue to fail to recognize its significance.

This lack of awareness is more profound (over 60% unaware) among women in higher-risk groups, racial and ethnic minorities, and has changed little in decades.

Poorly understood sex/gender differences in pathobiologic mechanisms, clinical presentation, management and application of diagnostic and therapeutic and preventive strategies have contributed to this gap. A critically important factor has been the underrepresentation of women in CVD research to date. In fact, only one-third of CVD clinical trials report sex-specific results despite The Food and Drug Administration regulations requiring sex stratification data, as well as the National Institute of Health recommendations of increased inclusion of women in clinical trials. This makes it difficult for researchers and clinicians to draw accurate conclusions about sex differences in mechanisms of disease, accuracy of specific diagnostic modalities and risks or benefits of a particular drug or device for the treatment of women with CVD. Furthermore, physicians and other healthcare providers continue to underestimate women's cardiovascular risk, in part because of utilization of traditional approaches which can lead to over-testing or inappropriate risk assessment without accurate differentiating who is truly at risk and inadequate use of preventive therapies for women.

The goal of this special edition Cardiovascular Innovations and Applications is to shed some light on specific topics that dominate the spectrum of CVD in women.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Scientists 3D print full-scale functioning heart components for the first time